These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 8941648)

  • 1. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
    Baker CJ; Rench MA; Paoletti LC; Edwards MS
    Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
    J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
    Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
    J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
    J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
    Palazzi DL; Rench MA; Edwards MS; Baker CJ
    J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
    Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Pinel J; Kasper DL
    J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
    Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
    J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
    Baker CJ; Rench MA; McInnes P
    Vaccine; 2003 Jul; 21(24):3468-72. PubMed ID: 12850362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
    Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
    J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk.
    Lagergård T; Thiringer K; Wassén L; Schneerson R; Trollfors B
    Eur J Pediatr; 1992 Feb; 151(2):98-102. PubMed ID: 1537371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
    Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.